1,000,000 Shares in Achillion Pharmaceuticals, Inc. (ACHN) Acquired by Artal Group S.A.

Artal Group S.A. purchased a new stake in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 1,000,000 shares of the biopharmaceutical company’s stock, valued at approximately $4,490,000. Artal Group S.A. owned 0.73% of Achillion Pharmaceuticals as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Dimensional Fund Advisors LP boosted its stake in Achillion Pharmaceuticals by 51.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 613,006 shares of the biopharmaceutical company’s stock worth $2,581,000 after purchasing an additional 207,204 shares during the period. Deschutes Portfolio Strategy LLC boosted its stake in Achillion Pharmaceuticals by 358.6% in the 2nd quarter. Deschutes Portfolio Strategy LLC now owns 116,630 shares of the biopharmaceutical company’s stock worth $535,000 after purchasing an additional 91,200 shares during the period. Senzar Asset Management LLC acquired a new position in Achillion Pharmaceuticals in the 2nd quarter worth $4,966,000. Bank of New York Mellon Corp boosted its stake in Achillion Pharmaceuticals by 11.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 611,634 shares of the biopharmaceutical company’s stock worth $2,808,000 after purchasing an additional 62,515 shares during the period. Finally, Credit Suisse AG boosted its stake in Achillion Pharmaceuticals by 106.0% in the 1st quarter. Credit Suisse AG now owns 237,819 shares of the biopharmaceutical company’s stock worth $1,002,000 after purchasing an additional 122,361 shares during the period. 75.70% of the stock is owned by institutional investors.

Achillion Pharmaceuticals, Inc. (ACHN) traded up $0.03 during trading on Monday, hitting $3.47. 621,590 shares of the stock were exchanged, compared to its average volume of 1,655,006. Achillion Pharmaceuticals, Inc. has a one year low of $2.95 and a one year high of $5.66.

Achillion Pharmaceuticals (NASDAQ:ACHN) last posted its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.14) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $0.04. During the same quarter last year, the company earned ($0.15) EPS. research analysts anticipate that Achillion Pharmaceuticals, Inc. will post -0.63 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “1,000,000 Shares in Achillion Pharmaceuticals, Inc. (ACHN) Acquired by Artal Group S.A.” was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://sportsperspectives.com/2017/11/20/1000000-shares-in-achillion-pharmaceuticals-inc-achn-acquired-by-artal-group-s-a.html.

ACHN has been the subject of a number of research analyst reports. BidaskClub lowered shares of Achillion Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, July 25th. ValuEngine lowered shares of Achillion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Monday, September 11th. Robert W. Baird reaffirmed a “neutral” rating and issued a $4.00 target price (down from $5.00) on shares of Achillion Pharmaceuticals in a research note on Tuesday, September 12th. Chardan Capital reaffirmed a “neutral” rating on shares of Achillion Pharmaceuticals in a research note on Sunday, September 17th. Finally, Zacks Investment Research raised shares of Achillion Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, September 14th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $5.29.

Achillion Pharmaceuticals Profile

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Want to see what other hedge funds are holding ACHN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN).

Institutional Ownership by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply